Robert R Webb

US Patent:

6652864, Nov 25, 2003

Filed:

Dec 21, 1998

Appl. No.:

09/217037

Inventors:

Robert R. Webb - Moss Beach CA
Constance A. McKee - Woodside CA

Assignee:

Asilomar Pharmaceuticals, Inc. - Woodside CA

International Classification:

A61K 3818

US Classification:

4241931, 4241941, 42419511

Abstract:

A compound for delivering a non-cytotoxic therapeutic moiety into nerve cells, the compound having the general formula: where: B is a binding agent capable of selectively binding to a nerve cell surface receptor and mediating absorption of the compound by the nerve cell; TM is a therapeutic moiety which has a non-cytotoxic therapeutic effect when absorbed by a nerve cell; and L is a linker coupling B to TM.

US Patent:

6664241, Dec 16, 2003

Filed:

May 29, 2001

Appl. No.:

09/870071

Inventors:

Conway C. Chang - Cambridge MA
Binh T. Dang - San Jose CA
Christopher J. Baldwin - Santa Cruz CA
David J. Loury - San Jose CA
Reyna J. Simon - Los Gatos CA
Robert R. Webb - Moss Beach CA

Assignee:

Micrologix Biotech Inc. - Vancouver

International Classification:

A61K 3170

US Classification:

514 31, 536 71

Abstract:

The present invention provides two new classes of polyene macrolide amide derivatives useful for treating or preventing fungal infections. The new polyene macrolide amide derivatives exhibit antifungal activity and are more water-soluble than conventional polyene antibiotics, such as amphotericin B and amphotericin B methyl ester.

US Patent:

7718605, May 18, 2010

Filed:

May 7, 2008

Appl. No.:

12/116886

Inventors:

Robert R. Webb - Moss Beach CA, US
Constance A. McKee - Woodside CA, US

Assignee:

Manzanita Pharmaceuticals, Inc. - Woodside CA

International Classification:

A61K 38/18
A61K 47/28
A61K 47/42
C07K 14/48

US Classification:

514 2, 530402

Abstract:

A compound for delivering a non-cytotoxic therapeutic moiety into nerve cells, the compound having the general formula:B-L-TMwhere:.

US Patent:

8232251, Jul 31, 2012

Filed:

Nov 25, 2008

Appl. No.:

12/323421

Inventors:

G. Craig Hill - Stockton CA, US
Stephen B. Kahl - Portola Valley CA, US
Robert R. Webb - Moss Beach CA, US
Constance A. McKee - Woodside CA, US

Assignee:

Manzanita Pharmaceuticals, Inc. - Woodside CA

International Classification:

A61K 38/16
A61K 47/28

US Classification:

514 212, 424 145

Abstract:

The invention features compounds of the general formula:B-L-Mwhere B is a binding agent capable of selectively binding to a nerve cell surface receptor and mediating absorption of the compound by the nerve cell; M is a moiety which performs a useful non-cytotoxic function when absorbed by a nerve cell, and can be a therapeutic moiety or an imaging moiety; and L is a linker coupling B to M. The invention also features methods of use of the compounds in, for example, treating conditions such as viral infections and pain, as well as in labeling nerve cells.

US Patent:

20040138437, Jul 15, 2004

Filed:

Oct 23, 2003

Appl. No.:

10/692420

Inventors:

Conway Chang - Cambridge MA, US
Binh Dang - San Jose CA, US
Christopher Baldwin - Santa Cruz CA, US
David Loury - San Jose CA, US
Reyna Simon - Los Gatos CA, US
Robert Webb - Moss Beach CA, US

Assignee:

Micrologix Biotech Inc. - Vancouver

International Classification:

C07H017/08

US Classification:

536/007100

Abstract:

The present invention provides two new classes of polyene macrolide amide derivatives useful for treating or preventing fungal infections. The new polyene macrolide amide derivatives exhibit antifungal activity and are more water-soluble than conventional polyene antibiotics, such as amphotericin B and amphotericin B methyl ester.

US Patent:

20070231263, Oct 4, 2007

Filed:

Nov 22, 2006

Appl. No.:

11/604178

Inventors:

Jun Qiu - San Diego CA, US
Robert Webb - San Diego CA, US
David Unett - San Deigo CA, US
Joel Gatlin - San Diego CA, US
Daniel Connolly - Solana Beach CA, US

International Classification:

A61K 48/00
A61K 31/44
A61K 49/00
C07D 417/00
C07K 14/00
C12N 5/06

US Classification:

424009100, 435366000, 514002000, 514336000, 530350000, 546268700

Abstract:

The present invention relates to methods of identifying whether one or more candidate compounds is a modulator of a G protein-coupled receptor (GPCR) or a modulator of blood glucose concentration. In certain embodiments, the GPCR is human. The present invention also relates to methods of using a modulator of the GPCR. A preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for lowering blood glucose concentration, for preventing or treating certain metabolic disorders, such as insulin resistance, impaired glucose tolerance, and diabetes, and for preventing or treating a complication of an elevated blood glucose concentration, such as atherosclerosis, heart disease, stroke, hypertension and peripheral vascular disease.

US Patent:

20080004263, Jan 3, 2008

Filed:

Mar 3, 2005

Appl. No.:

10/591061

Inventors:

Vincent Santora - Carlsbad CA, US
Jonathan Covel - San Diego CA, US
Rena Hayashi - San Diego CA, US
Robert Webb - San Diego CA, US

International Classification:

A61K 31/4545
A61K 31/454
A61K 31/5377
A61K 31/541
A61P 15/10
C07D 211/82
C07D 221/00
C07D 279/12
C07D 413/14
C12N 5/02

US Classification:

514227800, 435375000, 514236800, 514326000, 544130000, 544058200, 546194000, 546209000

Abstract:

The present invention relates to compounds Formula I (I) that are modulators of the follicle stimulating hormone (FSH) receptor and are useful in the treatment of infertility and related disorders.

US Patent:

20080306114, Dec 11, 2008

Filed:

Apr 12, 2005

Appl. No.:

11/578257

Inventors:

Jun Qiu - San Diego CA, US
Robert R. Webb - San Diego CA, US
David J. Unett - San Diego CA, US
Joel E. Gatlin - San Diego CA, US
Daniel T. Connolly - Solana Beach CA, US

Assignee:

Arena Pharmaceuticals, Inc - San Diego CA

International Classification:

A61K 31/445
G01N 33/566
C12N 5/06
A61P 9/00
C07D 417/00

US Classification:

514326, 436501, 546209, 435325

Abstract:

The present invention relates to methods of identifying whether one or more candidate compounds is a modulator of a G protein-coupled receptor (GPCR) or a modulator of blood glucose concentration. In certain embodiments, the GPCR is human. The present invention also relates to methods of using a modulator of the GPCR. A preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for lowering blood glucose concentration, for preventing or treating certain metabolic disorders, such as insulin resistance, impaired glucose tolerance, and diabetes, and for preventing or treating a complication of an elevated blood glucose concentration, such as atherosclerosis, heart disease, stroke, hypertension and peripheral vascular disease.

Address:

1471 Rio Grande Rd, Park City, UT 84098

VIN:

4S4BRDLC9B2423397

Make:

SUBARU

Model:

OUTBACK

Year:

2011